ライフサイエンスコーパス: plasma drug concentration

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 administered regularly to maintain a steady plasma drug concentration.

2 may cause clinically significant changes in plasma drug concentrations.

3 RI at day 2 correlated with early time point plasma drug concentrations.

4 and insensitive lung cell tumors in vivo at plasma drug concentrations achieved in RA patients under

5 However, the extremely low plasma drug concentrations achieved, in conjunction with

6 o apparent relationship was observed between plasma drug concentration and clinical response.

7 eveloped that shows sustained maintenance of plasma drug concentrations and drug efficacy for almost

8 , quantitative virologic responses in urine, plasma drug concentrations, and clinical outcome.

9 round the depot region and was correlated to plasma drug concentration at early time points (0-4days)

10 The cardiac tissue-to-plasma drug concentration gradient averaged approximatel

11 ity of point-of-care devices able to measure plasma drug concentration in a simple, automated, and co

12 Higher plasma drug concentrations in individual patients correl

13 f providing a formulation that could provide plasma drug concentrations in the region of 0.5-1.0ng/mL

14 d with factors that differentially influence plasma drug concentrations in the two disease stages.

15 Plasma drug concentrations measured in Indian children w

16 prolonging drugs with 15 time-matched QT and plasma drug concentration measurements.

17 of autophagy led to 50-fold increases in the plasma drug concentration of the viral integrase inhibit

18 Plasma drug concentrations of both agents were highly va

19 Plasma drug concentration peaked at the end of KB infusi

20 tic model to explore the effect of different plasma drug concentration profiles.

21 Brain:plasma drug concentration ratios were determined intraop

22 in the treatment of rheumatoid arthritis at plasma drug concentrations substantially higher than are

23 ic AED products may cause greater changes in plasma drug concentrations than generic substitutions of

24 The area under the plasma drug concentration - time curve for MFG1, MFG2, a

25 ams, and electrocardiographs) and testing of plasma drug concentrations took place during and after c

26 the lower and upper limits, respectively, of plasma drug concentrations used in clinical transplantat

27 Plasma drug concentrations were determined over the 13-d

28 Plasma drug concentrations were measured by high-perform

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。